Stock · COHANCE · Healthcare
COHANCE share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for COHANCE LIFESCIENCES LIMITED, refreshed every end-of-day run. A systematic, data-only read on COHANCE LIFESCIENCES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads COHANCE as two-way with a Crack Score of 65/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where COHANCE stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
83/100Fundamental axis
83/100Money flow
63/100Result pulse · Q4 FY26
40/100Technical evidence
downtrend frame (50 < 200 DMA)
rally testing a falling MA
RSI 52.3 (relief rally zone)
materially below 52w high
Fundamental evidence
net profit -78.54% YoY
profit down at least 20% YoY
result score 40.0/100 (weak)
YoY growth not accelerating
Red flags
below 200DMA (not a long-side trend)
profit collapse (-78.54% YoY)
Relative valuation
P/E (TTM)
95.0P/E vs sector
+1.9%Sector percentile
87PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for COHANCE are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the COHANCE chart, refreshed every end-of-day run.
The Crack Score, and how it is built65 / 100 · Constructive
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for COHANCE, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on COHANCE reads right now.
The editorial price read on COHANCE is mixed. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on COHANCE can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving COHANCE.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why COHANCE moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
COHANCE LIFESCIENCES LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
40 / 100Revenue
Rs 619 crNet profit
Rs 8 crEPS (quarter)
Rs 0.51| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +54.0% | +13.7% |
| Net profit | -78.5% | -71.4% |
| Net margin | +1.3% | |
Distorted by a prior-year base effect.
Figures are the Q4 FY26 result for COHANCE LIFESCIENCES LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter25 quarters on record
COHANCE LIFESCIENCES LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 31 Mar 2020. These are quarterly facts, not TTM valuation inputs.
COHANCE official result trail
25 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 619 cr | Rs 0.51 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 545 cr | Rs 0.96 | n/a | 40/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 556 cr | Rs 1.94 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 549 cr | Rs 1.28 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 402 cr | Rs 1.65 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 307 cr | Rs 3.26 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 258 cr | Rs 3.23 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 231 cr | Rs 2.39 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 253 cr | Rs 2.10 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 220 cr | Rs 1.84 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 231 cr | Rs 3.13 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 348 cr | Rs 4.74 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 369 cr | Rs 4.87 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 354 cr | Rs 4.23 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 278 cr | Rs 2.83 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 339 cr | Rs 4.22 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 364 cr | Rs 3.60 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 392 cr | Rs 6.29 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 301 cr | Rs 3.81 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 264 cr | Rs 4.13 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 259 cr | Rs 3.27 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 275 cr | Rs 4.46 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 237 cr | Rs 2.91 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 238 cr | Rs 7.19 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 185 cr | Rs 5.83 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
COHANCE LIFESCIENCES LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
2,269 crNet profit (TTM)
150 crEBIT (TTM)
244 crProfit before tax (TTM)
207 crNet margin (TTM)
6.6%Finance costs (TTM)
37.2 crBalance sheet, as filed 2026-03-31
Total assets
5,730 crShareholder equity
4,034 crTotal borrowings
170 crCash and equivalents
49.1 crInventory
562 crTrade receivables
681 crThe cash engine, latest filed year
Operating cash flow
368 crCapex
220 crFree cash flow
148 crInvesting flow
-255 crFinancing flow
-165 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 2,269 cr | 150 cr | 4,034 cr | 170 cr | 368 cr |
| FY25 | 1,198 cr | 265 cr | 1,841 cr | 78.1 cr | 288 cr |
| FY24 | 1,051 cr | 300 cr | 2,051 cr | 38.6 cr | 358 cr |
| FY23 | 1,340 cr | 411 cr | 1,735 cr | 69.2 cr | 451 cr |
| FY22 | 1,320 cr | 454 cr | 1,527 cr | 95.6 cr | 330 cr |
| FY21 | 1,010 cr | 362 cr | 1,181 cr | 141 cr | n/a |
Every figure is parsed from COHANCE LIFESCIENCES LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record27 earnings calls
Every COHANCE earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
COHANCE LIFESCIENCES LIMITED earnings calls on record
27 calls since 31 Aug 2020
Show 19 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from COHANCE LIFESCIENCES LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
COHANCE LIFESCIENCES LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of COHANCE LIFESCIENCES LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the COHANCE chart. Not a substitute for a registered research note.
| Ticker | COHANCE |
|---|---|
| Full name | COHANCE LIFESCIENCES LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE03QK01018 |
| Market-cap band | ~7,261 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | COHANCE |
Reference chartLevels in show
The daily frame the desk reads on COHANCE.
FAQ11 reader questions · AEO-eligible
The line on COHANCE, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the COHANCE share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on COHANCE. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for COHANCE?
The BazaarBaazi Crack Score for COHANCE is 65 out of 100 as of 21 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on COHANCE?
Strike-level option inventory for COHANCE is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is COHANCE in and which peers does BazaarBaazi track?
COHANCE sits in Healthcare (mid cap), indicative market cap ~7,261 cr (indicative), ISIN INE03QK01018. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on COHANCE LIFESCIENCES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the COHANCE view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on COHANCE is mixed, published in Systematic Read on 21 Jul 2026.
Is COHANCE a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, COHANCE LIFESCIENCES LIMITED sits in the Scanned tier with a setup score of 68/100 (technical 83, fundamental 83). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read COHANCE LIFESCIENCES LIMITED's earnings call transcripts?
BazaarBaazi indexes 27 COHANCE earnings calls going back to 2020-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was COHANCE LIFESCIENCES LIMITED's Q4 FY26 net profit?
COHANCE LIFESCIENCES LIMITED reported a net profit of Rs 8 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -78.5% year on year, a move distorted by a prior-year base effect. The figure is from the company's official NSE filing.
What was COHANCE LIFESCIENCES LIMITED's Q4 FY26 revenue?
COHANCE LIFESCIENCES LIMITED reported revenue of Rs 619 cr for Q4 FY26. That is +54.0% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate COHANCE LIFESCIENCES LIMITED's Q4 FY26 result?
BazaarBaazi gives COHANCE LIFESCIENCES LIMITED's Q4 FY26 result a Result Pulse of 40 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Cohance Lifesciences Ltd announced recently?
The most recent official filing on record for Cohance Lifesciences Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside COHANCE, each a living view refreshed every end-of-day run.